BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (brimonidine tartrate and timolol maleate) by Novartis is tartrate/timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Approved for elevated intraocular pressure (iop) in patients with glaucoma, ocular hypertension, replacement therapy due to inadequately controlled iop and 2 more indications. First approved in 2022.
Drug data last refreshed 20h ago
tartrate/timolol maleate ophthalmic solution is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of…
Worked on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.